Trial Profile
An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 11 Aug 2016
Price :
$35
*
At a glance
- Drugs Roniciclib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Aug 2015 New trial record